Recommendations for serogroup B meningococcal vaccine for persons 10 years and older

COMMITTEE ON INFECTIOUS DISEASES

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This policy statement provides recommendations for the prevention of serogroup B meningococcal disease through the use of 2 newly licensed serogroup B meningococcal vaccines: MenB-FHbp (Trumenba; Wyeth Pharmaceuticals, a subsidiary of Pfizer, Philadelphia, PA) and MenB-4C (Bexsero; Novartis Vaccines, Siena, Italy). Both vaccines are approved for use in persons 10 through 25 years of age. MenB-FHbp is licensed as a 2-or 3-dose series, and MenB-4C is licensed as a 2-dose series for all groups. Either vaccine is recommended for routine use in persons 10 years and older who are at increased risk of serogroup B meningococcal disease (category A recommendation). Persons at increased risk of meningococcal serogroup B disease include the following: (1) persons with persistent complement component diseases, including inherited or chronic deficiencies in C3, C5- C9, properdin, factor D, or factor H or persons receiving eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire, CT), a monoclonal antibody that acts as a terminal complement inhibitor by binding C5 and inhibiting cleavage of C5 to C5A; (2) persons with anatomic or functional asplenia, including sickle cell disease; and (3) healthy persons at increased risk because of a serogroup B meningococcal disease outbreak. Both serogroup B meningococcal vaccines have been shown to be safe and immunogenic and are licensed by the US Food and Drug Administration for individuals between the ages of 10 and 25 years. On the basis of epidemiologic and antibody persistence data, the American Academy of Pediatrics agrees with the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention that either vaccine may be administered to healthy adolescents and young adults 16 through 23 years of age (preferred ages are 16 through 18 years) to provide short-term protection against most strains of serogroup B meningococcal disease (category B recommendation).

Original languageEnglish (US)
Article numbere20161890
JournalPediatrics
Volume138
Issue number3
DOIs
StatePublished - Sep 1 2016

Fingerprint

Meningococcal Vaccines
Vaccines
Complement Inactivating Agents
Complement Factor D
Complement Factor H
Sickle Cell Anemia
Advisory Committees
United States Food and Drug Administration
Centers for Disease Control and Prevention (U.S.)
Serogroup
Vaccine
Person
Pharmaceutical Preparations
Italy
Disease Outbreaks
Young Adult
Immunization
Monoclonal Antibodies
Pediatrics
Antibodies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)
  • Arts and Humanities (miscellaneous)

Cite this

Recommendations for serogroup B meningococcal vaccine for persons 10 years and older. / COMMITTEE ON INFECTIOUS DISEASES.

In: Pediatrics, Vol. 138, No. 3, e20161890, 01.09.2016.

Research output: Contribution to journalArticle

COMMITTEE ON INFECTIOUS DISEASES. / Recommendations for serogroup B meningococcal vaccine for persons 10 years and older. In: Pediatrics. 2016 ; Vol. 138, No. 3.
@article{ec5d38007ad54b12ae29720de2fb0679,
title = "Recommendations for serogroup B meningococcal vaccine for persons 10 years and older",
abstract = "This policy statement provides recommendations for the prevention of serogroup B meningococcal disease through the use of 2 newly licensed serogroup B meningococcal vaccines: MenB-FHbp (Trumenba; Wyeth Pharmaceuticals, a subsidiary of Pfizer, Philadelphia, PA) and MenB-4C (Bexsero; Novartis Vaccines, Siena, Italy). Both vaccines are approved for use in persons 10 through 25 years of age. MenB-FHbp is licensed as a 2-or 3-dose series, and MenB-4C is licensed as a 2-dose series for all groups. Either vaccine is recommended for routine use in persons 10 years and older who are at increased risk of serogroup B meningococcal disease (category A recommendation). Persons at increased risk of meningococcal serogroup B disease include the following: (1) persons with persistent complement component diseases, including inherited or chronic deficiencies in C3, C5- C9, properdin, factor D, or factor H or persons receiving eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire, CT), a monoclonal antibody that acts as a terminal complement inhibitor by binding C5 and inhibiting cleavage of C5 to C5A; (2) persons with anatomic or functional asplenia, including sickle cell disease; and (3) healthy persons at increased risk because of a serogroup B meningococcal disease outbreak. Both serogroup B meningococcal vaccines have been shown to be safe and immunogenic and are licensed by the US Food and Drug Administration for individuals between the ages of 10 and 25 years. On the basis of epidemiologic and antibody persistence data, the American Academy of Pediatrics agrees with the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention that either vaccine may be administered to healthy adolescents and young adults 16 through 23 years of age (preferred ages are 16 through 18 years) to provide short-term protection against most strains of serogroup B meningococcal disease (category B recommendation).",
author = "{COMMITTEE ON INFECTIOUS DISEASES} and Byington, {Carrie L.} and Maldonado, {Yvonne A.} and Barnett, {Elizabeth D.} and Davies, {H. Dele} and Edwards, {Kathryn M.} and Ruth Lynfield and Munoz, {Flor M.} and Dawn Nolt and Nyquist, {Ann Christine} and Rathore, {Mobeen H.} and Sawyer, {Mark H.} and Steinbach, {William J.} and Tan, {Tina Q.} and Zaoutis, {Theoklis E.} and Bernstein, {Henry H.} and Brady, {Michael T.} and Jackson, {Mary Anne} and Kimberlin, {David W.} and Long, {Sarah S.} and Meissner, {H. Cody} and Douglas Campos-Outcalt and Cohn, {Amanda C.} and Farizo, {Karen M.} and Marc Fischer and Gellin, {Bruce G.} and Gorman, {Richard L.} and Natasha Halasa and Robinson, {Joan L.} and Jamie Deseda-Tous and Simon, {Geoffrey R.} and Starke, {Jeffrey R.} and Frantz, {Jennifer M.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1542/peds.2016-1890",
language = "English (US)",
volume = "138",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "3",

}

TY - JOUR

T1 - Recommendations for serogroup B meningococcal vaccine for persons 10 years and older

AU - COMMITTEE ON INFECTIOUS DISEASES

AU - Byington, Carrie L.

AU - Maldonado, Yvonne A.

AU - Barnett, Elizabeth D.

AU - Davies, H. Dele

AU - Edwards, Kathryn M.

AU - Lynfield, Ruth

AU - Munoz, Flor M.

AU - Nolt, Dawn

AU - Nyquist, Ann Christine

AU - Rathore, Mobeen H.

AU - Sawyer, Mark H.

AU - Steinbach, William J.

AU - Tan, Tina Q.

AU - Zaoutis, Theoklis E.

AU - Bernstein, Henry H.

AU - Brady, Michael T.

AU - Jackson, Mary Anne

AU - Kimberlin, David W.

AU - Long, Sarah S.

AU - Meissner, H. Cody

AU - Campos-Outcalt, Douglas

AU - Cohn, Amanda C.

AU - Farizo, Karen M.

AU - Fischer, Marc

AU - Gellin, Bruce G.

AU - Gorman, Richard L.

AU - Halasa, Natasha

AU - Robinson, Joan L.

AU - Deseda-Tous, Jamie

AU - Simon, Geoffrey R.

AU - Starke, Jeffrey R.

AU - Frantz, Jennifer M.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - This policy statement provides recommendations for the prevention of serogroup B meningococcal disease through the use of 2 newly licensed serogroup B meningococcal vaccines: MenB-FHbp (Trumenba; Wyeth Pharmaceuticals, a subsidiary of Pfizer, Philadelphia, PA) and MenB-4C (Bexsero; Novartis Vaccines, Siena, Italy). Both vaccines are approved for use in persons 10 through 25 years of age. MenB-FHbp is licensed as a 2-or 3-dose series, and MenB-4C is licensed as a 2-dose series for all groups. Either vaccine is recommended for routine use in persons 10 years and older who are at increased risk of serogroup B meningococcal disease (category A recommendation). Persons at increased risk of meningococcal serogroup B disease include the following: (1) persons with persistent complement component diseases, including inherited or chronic deficiencies in C3, C5- C9, properdin, factor D, or factor H or persons receiving eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire, CT), a monoclonal antibody that acts as a terminal complement inhibitor by binding C5 and inhibiting cleavage of C5 to C5A; (2) persons with anatomic or functional asplenia, including sickle cell disease; and (3) healthy persons at increased risk because of a serogroup B meningococcal disease outbreak. Both serogroup B meningococcal vaccines have been shown to be safe and immunogenic and are licensed by the US Food and Drug Administration for individuals between the ages of 10 and 25 years. On the basis of epidemiologic and antibody persistence data, the American Academy of Pediatrics agrees with the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention that either vaccine may be administered to healthy adolescents and young adults 16 through 23 years of age (preferred ages are 16 through 18 years) to provide short-term protection against most strains of serogroup B meningococcal disease (category B recommendation).

AB - This policy statement provides recommendations for the prevention of serogroup B meningococcal disease through the use of 2 newly licensed serogroup B meningococcal vaccines: MenB-FHbp (Trumenba; Wyeth Pharmaceuticals, a subsidiary of Pfizer, Philadelphia, PA) and MenB-4C (Bexsero; Novartis Vaccines, Siena, Italy). Both vaccines are approved for use in persons 10 through 25 years of age. MenB-FHbp is licensed as a 2-or 3-dose series, and MenB-4C is licensed as a 2-dose series for all groups. Either vaccine is recommended for routine use in persons 10 years and older who are at increased risk of serogroup B meningococcal disease (category A recommendation). Persons at increased risk of meningococcal serogroup B disease include the following: (1) persons with persistent complement component diseases, including inherited or chronic deficiencies in C3, C5- C9, properdin, factor D, or factor H or persons receiving eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire, CT), a monoclonal antibody that acts as a terminal complement inhibitor by binding C5 and inhibiting cleavage of C5 to C5A; (2) persons with anatomic or functional asplenia, including sickle cell disease; and (3) healthy persons at increased risk because of a serogroup B meningococcal disease outbreak. Both serogroup B meningococcal vaccines have been shown to be safe and immunogenic and are licensed by the US Food and Drug Administration for individuals between the ages of 10 and 25 years. On the basis of epidemiologic and antibody persistence data, the American Academy of Pediatrics agrees with the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention that either vaccine may be administered to healthy adolescents and young adults 16 through 23 years of age (preferred ages are 16 through 18 years) to provide short-term protection against most strains of serogroup B meningococcal disease (category B recommendation).

UR - http://www.scopus.com/inward/record.url?scp=84985995938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985995938&partnerID=8YFLogxK

U2 - 10.1542/peds.2016-1890

DO - 10.1542/peds.2016-1890

M3 - Article

VL - 138

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 3

M1 - e20161890

ER -